Wells Fargo & Company Issues Pessimistic Forecast for GE HealthCare Technologies (NASDAQ:GEHC) Stock Price

GE HealthCare Technologies (NASDAQ:GEHC) had its price target cut by research analysts at Wells Fargo & Company from $97.00 to $75.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 22.89% from the company’s previous close.

A number of other equities analysts have also commented on GEHC. Morgan Stanley raised their price objective on shares of GE HealthCare Technologies from $80.00 to $85.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Citigroup lowered their target price on shares of GE HealthCare Technologies from $88.00 to $84.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Evercore raised their target price on shares of GE HealthCare Technologies from $95.00 to $98.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Wall Street Zen downgraded shares of GE HealthCare Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Piper Sandler lowered their target price on shares of GE HealthCare Technologies from $96.00 to $88.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Hold” and an average price target of $80.67.

GE HealthCare Technologies Price Performance

GEHC stock opened at $61.03 on Thursday. The firm has a 50 day moving average of $73.28 and a 200-day moving average of $77.52. The company has a current ratio of 1.22, a quick ratio of 1.13 and a debt-to-equity ratio of 0.95. GE HealthCare Technologies has a 12 month low of $58.75 and a 12 month high of $89.77. The firm has a market capitalization of $27.76 billion, a P/E ratio of 14.60, a price-to-earnings-growth ratio of 1.38 and a beta of 0.75.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter last year, the business posted $1.01 earnings per share. GE HealthCare Technologies’s revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, sell-side analysts predict that GE HealthCare Technologies will post 4.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GE HealthCare Technologies news, insider Frank R. Jimenez purchased 1,750 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were purchased at an average cost of $60.45 per share, with a total value of $105,787.50. Following the completion of the purchase, the insider owned 93,932 shares of the company’s stock, valued at $5,678,189.40. The trade was a 1.90% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter J. Arduini purchased 4,169 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were acquired at an average cost of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the purchase, the chief executive officer directly owned 259,424 shares of the company’s stock, valued at approximately $15,544,686.08. This represents a 1.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 9,229 shares of company stock valued at $556,180. 0.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in GEHC. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of GE HealthCare Technologies by 130.7% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 346 shares of the company’s stock worth $26,000 after acquiring an additional 196 shares in the last quarter. Godsey & Gibb Inc. purchased a new position in shares of GE HealthCare Technologies during the third quarter worth approximately $26,000. Laurel Wealth Advisors LLC purchased a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $26,000. Optima Capital LLC purchased a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Finally, Godfrey Financial Associates Inc. purchased a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Insiders are buying shares — CEO Peter Arduini, CFO James Saccaro and director Frank R. Jimenez increased positions (multiple Form 4 filings), which investors often interpret as management confidence in the company’s outlook. Read More. • Read More. • Read More.
• Positive Sentiment: Heavy call-option buying — an unusual surge in call volume suggests short-term bullish/speculative interest that can amplify upside moves. (No article link available)
• Neutral Sentiment: Wells Fargo lowered its price target to $75 but kept an overweight rating, signaling upside exists vs. current levels while tempering near-term expectations. Read More.
• Neutral Sentiment: Operational changes — GEHC announced a reorganization (Imaging + Advanced Visualization) and executive moves intended to improve execution; benefits could take multiple quarters to materialize. Read More.
• Negative Sentiment: Guidance cut and margin pressure — management trimmed FY26 EPS guidance to $4.80–5.00, citing inflation, higher component and freight costs and supply issues; this is the core reason for recent downside pressure. Read More.
• Negative Sentiment: Mixed Q1 results — revenue beat (~$5.13B) but EPS missed ($0.99 vs. $1.07 est.) and margins compressed, reinforcing short‑term risk to earnings. Read More.
• Negative Sentiment: Analyst downgrades / price‑target cuts — Citigroup, JPMorgan and others trimmed targets and ratings (e.g., PTs cut to ~$65–75), pulling sell‑side support lower and contributing to volatility. Read More.
• Negative Sentiment: Investor litigation inquiry — a Johnson Fistel investigation adds headline and legal risk that could increase volatility. Read More.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.